Clinical trial
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
NCT03285321
Study timeline
Study start (actual)2017-09-15Date precision: day
Registry last updated2026-01-20
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Non-small Cell Lung Cancerunresolved
Interventions
NivolumabDRUG · verified · RxNorm: nivolumab
NivolumabDRUG · verified · RxNorm: nivolumab
IpilimumabDRUG · verified · RxNorm: ipilimumab
Sponsors & collaborators
Greg Durm, MDlead sponsor
Bristol-Myers Squibbcollaborator
Big Ten Cancer Research Consortiumcollaborator
Mapped research locations
ChicagoIllinois, United States2BaltimoreMaryland, United States1IndianapolisIndiana, United States1MinneapolisMinnesota, United States1DetroitMichigan, United States1OmahaNebraska, United States1LouisvilleKentucky, United States1MadisonWisconsin, United States1New BrunswickNew Jersey, United States1HersheyPennsylvania, United States1LansingMichigan, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03285321 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.